

# Completion of first commercial scans at I-MED

9 December 2021

4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”), a medical technology company focused on commercialising its FDA-cleared and TGA-approved respiratory imaging platform, is pleased to announce completion of the first respiratory scans on a commercial basis with I-MED Radiology Network (“I-MED”), Australia’s largest diagnostic imaging provider.

The completion of the first commercial scans at I-MED’s clinic in Berwick follows the ASX announcement on 23 November 2021 detailing the commencement of 4DMedical’s commercial rollout with I-MED. Completion of the first commercial scans utilising 4DMedical’s proprietary XV Lung Ventilation Analysis Software (XV LVAS™) represents a significant milestone for the Company.

4DMedical has a strategy to make state-of-the-art respiratory scans and reports available to general practitioners and specialists on a pay-per-scan basis. The commencement of this commercial arrangement follows the successful completion of comprehensive piloting programs conducted at multiple clinical locations by 4DMedical in collaboration with I-MED.

The successful commercial rollout in Australia validates 4DMedical’s revenue generation strategy and will be followed by expansion into other metropolitan and regional centres early next year. Beyond Australia, the Company also has several pilot programs operating in the large and valuable United States market which it expects to convert to commercial relationships during 2022.

## 4DMedical Founder and CEO, Andreas Fouras, said:

“Clinicians in the Casey region can refer a patient for four-dimensional respiratory scanning now. The ability for these GPs and respiratory specialists to interpret ventilation reports that inform interventions and treatment is a world’s first achievement in improving patient care.

“I-MED Radiology Network is Australia’s largest diagnostic imaging provider”, added Dr Fouras. “Beyond putting our innovative technology within reach of more people, this also provides a solid basis for optimising commercial revenue.”

–ENDS–

Authorised on behalf of the 4DMedical Board of Directors by Andreas Fouras, CEO.

## Contacts

### Corporate

Charlene Stahr  
Company Secretary  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### Investor

Simon Hinsley  
+ 61 401 809 653  
[shinsley@4dmedical.com](mailto:shinsley@4dmedical.com)

### Media

Matthew Wright  
+ 61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## About 4DMedical

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).



4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. Through its technology, 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.